poisar

Stocks · News reference

Evommune Enters Exclusive License Agreement with Hinova Pharmaceuticals for EVO570

Fiscal.ai

Evommune has secured worldwide rights, excluding Greater China, to develop and commercialize the oral VAV1-directed molecular glue degrader EVO570.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Evommune, Inc. (EVMN)

    Filed: 2026-11-17 AccNo: 0001193125-26-465600 Size: 181 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers